NEW NURSE - OCTOBER 2000 - NHSGGC
Most of the following articles are available online via the NHS Scotland eLibrary. Please use the links where provided and your ATHENS password. A complete list of available online journals and registration for ATHENS can be found at
If you would like to request print copies of any of the articles please contact your nearest library or visit the library website for further details.
Please note inter-library requests will only be done for South Glasgow NHS staff.
Please note, the articles you are accessing may be protected by copyright legislation, please contact your librarian for a copyright declaration form if you are in any doubt. Or, consult the Copyright Licensing Agency at
If you have any questions regarding this or any other library services please contact your librarian.
Compiled by C. Boulnois
Library Services Manager (South)
NHS Greater Glasgow & Clyde Library Network
Central Library
Southern General Hospital
1345 Govan Rd
G51 4TF
0141 201 2163
charlotte.boulnois@sgh.scot.nhs.uk
References
1. Alcina A, Fedetz M, Ndagire D, et al. The T244I variant of the interleukin-7 receptor-alpha gene and multiple sclerosis. Tissue Antigens. 2008; 72(2):158-161.
2. Alvarez-Lafuente R, Garcia-Montojo M, De Las Heras V, et al. Herpesviruses and human endogenous retroviral sequences in the cerebrospinal fluid of multiple sclerosis patients. Multiple Sclerosis. 2008; 14(5):595-601.
3. Amato MP, Portaccio E, Stromillo ML, et al. Cognitive assessmetn and quantitative magnetic resonance metrics can help to identify benign multiple slcerosis. Neurology. 2008; 71(9):632-638.
4. Arnett PA, Barwick FH, Beeney JE. Depression in multiple sclerosis: Review and theoretical proposal. Journal of the International Neuropsychological Society. 2008; 14(5):691-724.
5. Ban M, Elson J, Walton A, et al. Investigation of the role of mitochondrial DNA in multiple sclerosis susceptibility. PLoS ONE. 2008; 3(8):Arte Number: e2891. ate of Pubaton: 06 Aug 2008.
6. Barach A, Derrick S, Fahmi R, Toomey S, Smith C, Hale L. Perceptions of the effects of fatigue on daily physical activity in people with multiple sclerosis. Nz J Physiother. 2008; 36(2):83.
7. Barcellos LF, Ramsay PP, Caillier SJ, et al. Genetic variation in nitric oxide synthase 2A (NOS2A) and risk for multiple sclerosis. Genes Immun. 2008; 9(6):493-500.
8. Benedict RH, Shucard JL, Zivadinov R, Shucard DW. Neuropsychological impairment in systemic lupus erythematosus: A comparison with multiple sclerosis. Neuropsychol Rev. 2008; 18(2):149-166.
9. Benedict RHB, Hussein S, Englert J, et al. Cortical atrophy and personality in multiple sclerosis. Neuropsychology. 2008; 22(4):432-441.
10. Benedict RHB, Munschauer F, Zarevics P, et al. Effects of l-amphetamine sulfate on cognitive function in multiple sclerosis patients. J Neurol. 2008; 255(6):848-852.
11. Berger JR. Paradoxically aggressive multiple sclerosis in the face of natalizumab therapy. Multiple Sclerosis. 2008; 14(5):708-710.
12. Berthelot L, Laplaud DA, Pettre S, et al. Blood CD8+ T cell responses against myelin determinants in multiple sclerosis and healthy individuals. Eur J Immunol. 2008; 38(7):1889-1899.
13. Binns EE, Taylor D. Does tai chi improve strength and balance in people with multiple sclerosis -- the current literature. Nz J Physiother. 2008; 36(2):83.
14. Blanco Y, Compta Y, Graus F, Saiz A. Midbrain lesions and paroxysmal dysarthria in multiple sclerosis. Multiple Sclerosis. 2008; 14(5):694-697.
15. Brahmachari S, Pahan K. Role of cytokine p40 family in multiple sclerosis. Minerva Med. 2008; 99(2):105-118.
16. Bramow S, Faber-Rod JC, Jacobsen C, et al. Fatal neurogenic pulmonary edema in a patient with progressive multiple sclerosis. Multiple Sclerosis. 2008; 14(5):711-715.
17. Bryan J. Interferon: The drug that changed our understanding of multiple sclerosis. Pharmaceutical Journal. 2008; 281(7513):139-140.
18. Campagnolo DI. Monoclonal antibodies: A new way to treat MS... multiple sclerosis. Ms Q Rep. 2008; 27(2):10-14.
19. Castellano V, Patel DI, White LJ. Cytokine responses to acute and chronic exercise in multiple sclerosis. J Appl Physiol. 2008; 104(6):1697-1702.
20. Cettomai D, Pulicken M, Gordon-Lipkin E, et al. Reproducibility of optical coherence tomography in multiple sclerosis. Archives of Neurology. 2008; 65(9):1218-1222.
21. Chang A, Smith MC, Yin X, Fox RJ, Staugaitis SM, Trapp BD. Neurogenesis in the chronic lesions of multiple sclerosis. Brain. 2008; 131(9):2366-2375.
22. Charach G, Grosskopf I, Weintraub M. Development of crohn's disease in a patient with multiple sclerosis treated with copaxone. Digestion. 2008; 77(3-4):198-200.
23. Chen Z, Freedman MS. CD16+ gammadelta T cells mediate antibody dependent cellular cytotoxicity: Potential mechanism in the pathogenesis of multiple sclerosis. Clinical Immunology. 2008; 128(2):219-227.
24. Chiasserini D, Di Filippo M, Candeliere A, et al. CSF proteome analysis in multiple sclerosis patients by two-dimensional electrophoresis. European Journal of Neurology. 2008; 15(9):998-1001.
25. Chopra P, Herrman H, Kennedy G. Comparison of disability and quality of life measures in patients with long-term psychotic disorders and patients with multiple sclerosis: An application of the WHO disability assessment schedule II and WHO quality of life-BREF. Int J Rehabil Res. 2008; 31(2):141-149.
26. Clerico M, Faggiano F, Palace J, Rice G, Tintore M, Durelli L. Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis. Cochrane Database Syst Rev. 2008; (2).
27. Contini C, Seraceni S, Castellazzi M, Granieri E, Fainardi E. Chlamydophila pneumoniae DNA and mRNA transcript levels in peripheral blood mononuclear cells and cerebrospinal fluid of patients with multiple sclerosis. Neurosci Res. 2008; 62(1):58-61.
28. Correale J, Farez M, Razzitte G. Helminth infections associated with multiple sclerosis induce regulatory B cells. Annals of Neurology. 2008; 64(2):187-199.
29. Corvol J-, Pelletier D, Henry RG, et al. Abrogation of T cell quiescence characterizes patients at high risk for multiple sclerosis after the initial neurological event. Proc Natl Acad Sci U S A. 2008; 105(33):11839-11844.
30. Cournu-Rebeix I, Genin E, Leray E, et al. HLA-DRB1* 15 allele influences the later course of relapsing remitting multiple sclerosis. Genes Immun. 2008; 9(6):570-574.
31. Debouverie M, Pittion-Vouyovitch S, Louis S, Guillemin F. Natural history of multiple sclerosis in a population-based cohort. European Journal of Neurology. 2008; 15(9):916-921.
32. Dwyer T, van der Mei, I., Ponsonby AL, et al. Melanocortin 1 receptor genotype past environmental sun exposure and risk of multiple sclerosis. Neurology. 2008; 71(8):583-589.
33. Ebers GC, Heigenhauser L, Daumer M, Lederer C, Noseworthy JH. Disability as an outcome in MS clinical trials. Neurology. 2008; 71(9):624-631.
34. Fazekas F. Lublin FD. Li D. Freedman MS. Hartung HP. Rieckmann P. Sorensen PS. Maas-Enriquez M. Sommerauer B. Hanna K. PRIVIG Study Group. UBC MS/MRI Research Group. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: A dose-finding trial. Neurology. 2008; 71(4):265-271.
35. Fernandez-Morera JL, Rodriguez-Rodero S, Tunon A, et al. Genetic influence of the nonclassical major histocompatibility complex class I molecule MICB in multiple sclerosis susceptibility. Tissue Antigens. 2008; 72(1):54-59.
36. Freedman MS, Hughes B, Mikol DD, et al. Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: A systematic comparison. Eur Neurol. 2008; 60(1):1-11.
37. Gaines JJ, Gavett RA, Lynch JJ, Bakshi R, Benedict RHB. New error type and recall consistency indices for the brief visuospatial memory test - revised: Performance in healthy adults and multiple sclerosis patients. Clin Neuropsychol. 2008; 22(5):851-863.
38. Gani R, Giovannoni G, Bates D, Kemball B, Hughes S, Kerrigan J. Cost-effectiveness analyses of natalizumab (tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. Pharmacoeconomics. 2008; 26(7):617-627.
39. Garay L, Gonzalez Deniselle MC, Gierman L, et al. Steroid protection in the experimental autoimmune encephalomyelitis model of multiple sclerosis. Neuroimmunomodulation. 2008; 15(1):76-83.
40. Gatti R, Corti M, Govetto S, Bonzani K, Boccardi S. Electromyographic activity to keep a lower limb in a raised position in healthy subjects and subjects with multiple sclerosis. Multiple Sclerosis. 2008; 14(5):691-693.
41. Ghezzi A, Zaffaroni M. Female-specific issues in multiple sclerosis. Expert Review of Neurotherapeutics. 2008; 8(6):969-977.
42. Giesser. Exercise and gait retraining in persons with multiple sclerosis. Ms Q Rep. 2008; 27(2):15-18.
43. Golan D, Somer E, Dishon S, Cuzin-Disegni L, Miller A. Impact of exposure to war stress on exacerbations of multiple sclerosis. Annals of Neurology. 2008; 64(2):143-148.
44. Goodin DS, Cohen BA, O'Connor P, Kappos L, Stevens JC. Assessment: The use of natalizumab (tysabri) for the treatment of multiple sclerosis (an evidence based review): Report of the therapeutics and technology assessment subcommittee of the american academy of neurology. Neurology. 2008; 71(10):766-773.
45. Grover LK, Hood DC, Ghadiali Q, et al. A comparison of multifocal and conventional visual evoked potential techniques in patients with optic neuritis/multiple sclerosis. Documenta Ophthalmologica. 2008; 117(2):121-128.
46. Gusev YI, Banach M, Simonow A, et al. Efficacy and safety of botulinum type A toxin in adductor spasticity due to multiple sclerosis. J Musculoskeletal Pain. 2008; 16(3):175-188.
47. Harbige LS, Pinto E, Xiang M, Leach M, Sharief MK. PUFA in the pathogenesis and treatment of patients with multiple sclerosis. Proc Nutr Soc. 2008; 67(OCE):E21.
48. Harp CT, Lovett-Racke AE, Racke MK, Frohman EM, Monson NL. Impact of myelin-specific antigen presenting B cells on T cell activation in multiple sclerosis. Clinical Immunology. 2008; 128(3):382-391.
49. Hart SL, Vella L, Mohr DC. Relationships among depressive symptoms, benefit-finding, optimism, and positive affect in multiple sclerosis patients after psychotherapy for depression. Health Psychology. 2008; 27(2):230-238.
50. Hayes CE, Donald Acheson E. A unifying multiple sclerosis etiology linking virus infection, sunlight, and vitamin D, through viral interleukin-10. Med Hypotheses. 2008; 71(1):85-90.
51. Hebb AL, Moore CS, Bhan V, et al. Expression of the inhibitor of apoptosis protein family in multiple sclerosis reveals a potential immunomodulatory role during autoimmune mediated demyelination. Multiple Sclerosis. 2008; 14(5):577-594.
52. Held U, Steyer K, Menzler S, Kucheahoff H, Daumer M. Evaluation of some alternative designs for phase 2 multiple sclerosis trials - A simulation study. Drug Inf J. 2008; 42(4):359-367.
53. Hellings N, Stinissen P. Tovaxin, radiation-attenuated, patient-specific T-cells for the therapeutic vaccination of multiple sclerosis. Current Opinion in Investigational Drugs. 2008; 9(5):534-540.
54. Hirst C, Ingram G, Swingler R, Compston DA,S., Pickersgill T, Robertson NP. Change in disability in patients with multiple sclerosis: A 20-year prospective population-based analysis. Journal of Neurology, Neurosurgery and Psychiatry. 2008; 79(10):1137-1143.
55. Hoegerl C, Zboray S. Pathological laughter in a patient with multiple sclerosis. J Am Osteopath Assoc. 2008; 108(8):409-411.
56. Hoffmann S, Cepok S, Grummel V, et al. HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis. Am J Hum Genet. 2008; 83(2):219-227.
57. Holmoy T. The immunology of multiple sclerosis: Disease mechanisms and therapeutic targets. Minerva Med. 2008; 99(2):119-140.
58. Hoppenbrouwers IA, Aulchenko YS, Ebers GC, et al. EVI5 is a risk gene for multiple sclerosis. Genes & Immunity. 2008; 9(4):334-337.
59. Husain S, Yildirim-Toruner C, Rubio JP, et al. Variants of ST8SIA1 are associated with risk of developing multiple sclerosis. PLoS ONE. 2008; 3(7):Arte Number: e2653. ate of Pubaton: 09 Ju 2008.
60. Invernizzi P, Benedetti MD, Poli S, Monaco S. Azathioprine in multiple sclerosis. Mini-Reviews in Medicinal Chemistry. 2008; 8(9):919-926.
61. Jarius S, Franciotta D, Bergamaschi R, et al. Polyspecific antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica. Journal of Neurology, Neurosurgery and Psychiatry. 2008; 79(10):1134-1136.
62. Jozefowicz-Korczynska M, Lukomski M, Pajor A. Identification of internuclear ophthalmoplegia signs in multiple sclerosis patients: Saccade test analysis. J Neurol. 2008; 255(7):1006-1011.
63. Kalmar JH, Gaudino EA, Moore NB, Halper J, DeLuca J. The relationship between cognitive deficits and everyday functional activities in multiple sclerosis. Neuropsychology. 2008; 22(4):442-449.
64. Kanzaki M, Mochizuki H, Ogawa G, et al. Clinical features of opticospinal multiple sclerosis with anti-aquaporin 4 antibody. Eur Neurol. 2008; 60(1):37-42.
65. Karpatkin H. Clinical point of view. respiratory changes in multiple sclerosis. J Neurol Phys Ther. 2008; 32(2):105.
66. Karper WB. The holistic effects of long-term exercise, health education, and resource assistance on one woman with multiple debilitating medical problems: A case report. Holist Nurs Pract. 2008; 22(4):206-209.
67. Katsara M, Matsoukas J, Deraos G, Apostolopoulos V. Towards immunotherapeutic drugs and vaccines against multiple sclerosis. Acta Biochimica et Biophysica Sinica. 2008; 40(7):636-642.
68. Kinter J, Zeis T, Schaeren-Wiemers N. RNA profiling of MS brain tissues. International MS Journal. 2008; 15(2):51-58.
69. Ko MW, Tamhankar MA, Volpe NJ, Porter D, McGrath C, Galetta SL. Acute promyelocytic leukemic involvement of the optic nerves following mitoxantrone treatment for multiple sclerosis. J Neurol Sci. 2008; 273(1-2):144-147.
70. Krakauer M, Sorensen P, Khademi M, Olsson T, Sellebjerg F. Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: Interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression. Multiple Sclerosis. 2008; 14(5):622-630.
71. Kuenz B, Lutterotti A, Ehling R, et al. Cerebrospinal fluid B cells correlate with early brain inflammation in multiple sclerosis. PLoS ONE. 2008; 3(7):Arte Number: e2559. ate of Pubaton: 02 Ju 2008.
72. Kulbatski I, Mothe AJ, Parr AM, et al. Glial precursor cell transplantation therapy for neurotrauma and multiple sclerosis. Prog Histochem Cytochem. 2008; 43(3):123-176.
73. Lam S, Wang S, Gottesman M. Interferon-beta1b for the treatment of multiple sclerosis. Expert Opinion on Drug Metabolism and Toxicology. 2008; 4(8):1111-1117.
74. Leete M, Kayes NM, Mawston G, et al. Exploring actical accelerometers as an objective measure of physical activity in people with multiple sclerosis. Nz J Physiother. 2008; 36(2):87.
75. Lewy H, Rotstein A, Kahana E, Marrosu MG, Cocco E, Laron Z. Juvenile multiple sclerosis similar to type I diabetes mellitus has a seasonality of month of birth which differs from that in the general population. J Pediatr Endocrinol. 2008; 21(5):473-477.
76. Lincoln JA, Hankiewicz K, Cook SD. Could epstein-barr virus or canine distemper virus cause multiple sclerosis?. Neurol Clin. 2008; 26(3):699-715.
77. Lowe MJ, Beall EB, Sakaie KE, et al. Resting state sensorimotor functional connectivity in multiple sclerosis inversely correlates with transcallosal motor pathway transverse diffusivity. Hum Brain Mapp. 2008; 29(7):818-827.
78. Lunemann JD, Jelcic I, Roberts S, et al. EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2. J Exp Med. 2008; 205(8):1763-1773.
79. Macniven JAB, Davis C, Ho M-, Bradshaw CM, Szabadi E, Constantinescu CS. Stroop performance in multiple sclerosis: Information processing, selective attention, or executive functioning?. Journal of the International Neuropsychological Society. 2008; 14(5):805-814.
80. Mandrioli J, Sola P, Bedin R, Gambini M, Merelli E. A multifactorial prognostic index in multiple sclerosis: Cerebrospinal fluid IgM oligoclonal bands and clinical features to predict the evolution of the disease. J Neurol. 2008; 255(7):1023-1031.
81. Marcotte TD, Rosenthal TJ, Roberts E, et al. The contribution of cognition and spasticity to driving performance in multiple sclerosis. Archives of Physical Medicine and Rehabilitation. 2008; 89(9):1753-1758.
82. Martinez A, Santiago JL, Cenit MC, et al. IFIH1-GCA-KCNH7 locus: Influence on multiple sclerosis risk. European Journal of Human Genetics. 2008; 16(7):861-864.
83. McKeage K. Interferon-beta-1b: In newly emerging multiple sclerosis. CNS Drugs. 2008; 22(9):787-792.
84. Merwick A, Sweeney BJ. Functional symptoms in clinically definite MS - pseudo-relapse syndrome. International MS Journal. 2008; 15(2):47-51.
85. Mesaros S, Rovaris M, Pagani E, et al. A magnetic resonance imaging voxel-based morphometry study of regional gray matter atrophy in patients with benign multiple sclerosis. Archives of Neurology. 2008; 65(9):1223-1230.
86. Michalowska-Wender G, Wender M. Peripheral blood cell immunomarkers in the course of methylprednisolone treatment of multiple sclerosis relapses. Folia Neuropathologica. 2008; 46(2):134-138.
87. Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs glatiramer acetate in relapsing MS disease [REGARD] study): A multicentre, randomised, parallel, open-label trial. Lancet Neurology. 2008; 7(10):903-914.
88. Minden S, Hoaglin D, Jureidini S, et al. Disease-modifying agents in the sonya slifka longitudinal multiple sclerosis study. Multiple Sclerosis. 2008; 14(5):640-655.
89. Motl RW. Physical activity and its measurement and determinants in multiple sclerosis. Minerva Med. 2008; 99(2):157-165.
90. Nicoletti A, Patti F, Lo Fermo S, et al. Frequency of celiac disease is not increased among multiple sclerosis patients. Multiple Sclerosis. 2008; 14(5):698-700.
91. Nociti V, Batocchi AP, Bartalini S, et al. Somatosensory evoked potentials reflect the upper limb motor performance in multiple sclerosis. J Neurol Sci. 2008; 273(1-2):99-102.
92. Nunez C, Dema B, Cenit MC, et al. IL23R: A susceptibility locus for celiac disease and multiple sclerosis?. Genes & Immunity. 2008; 9(4):289-293.
93. Ortler S, Leder C, Mittelbronn M, et al. B7-H1 restricts neuroantigen-specific T cell responses and confines inflammatory CNS damage: Implications for the lesion pathogenesis of multiple sclerosis. Eur J Immunol. 2008; 38(6):1734-1744.
94. Orton S, Morris AP, Herrera BM, et al. Evidence for genetic regulation of vitamin D status in twins with multiple sclerosis. Am J Clin Nutr. 2008; 88(2):441-447.
95. O'Sullivan RJ, Brown IG, Pender MP. Apneusis responding to buspirone in multiple sclerosis. Multiple Sclerosis. 2008; 14(5):705-707.
96. Pakenham KI. Making sense of caregiving for persons with multiple sclerosis (MS): The dimensional structure of sense making and relations with positive and negative adjustment. Int J Behav Med. 2008; 15(3):241-252.
97. Penton-Rol G, Cervantes-Llanos M, Cabrera-Gomez JA, et al. Treatment with type I interferons induces a regulatory T cell subset in peripheral blood mononuclear cells from multiple sclerosis patients. Int Immunopharmacol. 2008; 8(6):881-886.
98. Politte LC, Huffman JC, Stern TA. Neuropsychiatric manifestations of multiple sclerosis. Primary Care Companion to the Journal of Clinical Psychiatry. 2008; 10(4):318-324.
99. Prakash RS, Erickson KI, Snook EM, Colcombe SJ, Motl RW, Kramer AF. Cortical recruitment during selective attention in multiple sclerosis: An fMRI investigation of individual differences. Neuropsychologia. 2008; 46(12):2888-2895.
100. Prunty M, Sharpe L, Butow P, Fulcher G. The motherhood choice: Themes arising in the decision-making process for women with multiple sclerosis. Multiple Sclerosis. 2008; 14(5):701-704.
101. Pueyo V, Martin J, Fernandez J, et al. Axonal loss in the retinal nerve fiber layer in patients with multiple sclerosis. Multiple Sclerosis. 2008; 14(5):609-614.
102. Ramagopalan SV, Valdar W, Dyment DA, et al. No effect of preterm birth on the risk of multiple sclerosis: A population based study. .
103. Ramagopalan SV, Valdar W, Dyment DA, et al. No effect of preterm birth on the risk of multiple sclerosis: A population based study. BMC Neurology. 2008; 8:30.
104. Roosendaal SD, Moraal B, Vrenken H, et al. In vivo MR imaging of hippocampal lesions in multiple sclerosis. Journal of Magnetic Resonance Imaging. 2008; 27(4):726-731.
105. Rovira A, Leon A. MR in the diagnosis and monitoring of multiple sclerosis: An overview. Eur J Radiol. 2008; 67(3):409-414.
106. Saari A, Tolonen U, Paakko E, et al. Sympathetic skin responses in multiple sclerosis. Acta Neurologicia Scandinavica. 2008; 118(4):226-231.
107. Satoh J-, Misawa T, Tabunoki H, Yamamura T. Molecular network analysis of T-cell transcriptome suggests aberrant regulation of gene expression by NF-kappaB as a biomarker for relapse of multiple sclerosis. Dis Markers. 2008; 25(1):27-35.
108. Sellebjerg F, Datta P, Larsen J, et al. Gene expression analysis of interferon-beta treatment in multiple sclerosis. Multiple Sclerosis. 2008; 14(5):615-621.
109. Serana F, Sottini A, Ghidini C, et al. Modulation of IFNAR1 mRNA expression in multiple sclerosis patients. J Neuroimmunol. 2008; 197(1):54-62.
110. Sharma KR, Saadia D, Facca AG, Bhatia R, Ayyar DR, Sheremata W. Chronic inflammatory demyelinating polyradiculoneuropathy associated with multiple sclerosis. Journal of Clinical Neuromuscular Disease. 2008; 9(4):385-396.
111. Sheremata WA, Jy W, Horstman LL, Ahn YS, Alexander JS, Minagar A. Evidence of platelet activation in multiple sclerosis. Journal of Neuroinflammation. 2008; 5:27.
112. Siegel SD, Turner AP, Haselkorn JK. Adherence to disease-modifying therapies in multiple sclerosis: Does caregiver social support matter? Rehabil Psychol. 2008; 53(1):73-79.
113. Siepman TAM, Janssens ACJW, De Koning I, Polman CH, Boringa JB, Hintzen RQ. The role of disability and depression in cognitive functioning within 2 years after multiple sclerosis diagnosis. J Neurol. 2008; 255(6):910-916.
114. Signal NEJ, Boston LR. The relationship between fatigue and depression in people with multiple sclerosis. Nz J Physiother. 2008; 36(2):92.
115. Siniscalchi A, Gallelli L, De Sarro G. Drugs treatment of pain in multiple sclerosis. Current Clinical Pharmacology. 2007; 2(3):227-233.
116. Smith CM, Hale LA, Schneiders AG, Olson K. How does the experience of fatigue in people with multiple sclerosis change during an eight week exercise programme? Nz J Physiother. 2008; 36(2):92-93.
117. Sotgiu S, Musumeci S, Marconi S, Gini B, Bonetti B. Different content of chitin-like polysaccharides in multiple sclerosis and alzheimer's disease brains. J Neuroimmunol. 2008; 197(1):70-73.
118. Svejgaard A. The immunogenetics of multiple sclerosis. Immunogenetics. 2008; 60(6):275-286.
119. Szabo K, Kern R, Griebe M, Baezner H, Hennerici MG, Gass A. Magnetic resonance imaging demonstration of fascicular inflammation in sixth nerve palsy as the presenting symptom in multiple sclerosis. Eur Neurol. 2008; 60(2):92-94.
120. Thickbroom GW, Sacco P, Faulkner DL, Kermode AG, Mastaglia FL. Enhanced corticomotor excitability with dynamic fatiguing exercise of the lower limb in multiple sclerosis. J Neurol. 2008; 255(7):1001-1005.
121. Thompson JP, Noyes K, Dorsey ER, Schwid SR, Holloway RG. Quantitative risk-benefit analysis of natalizumab. Neurology. 2008; 71(5):357-364.
122. Van Der Linden FAH, D'Hooghe MB, Nagels G, Van Nunen A, Polman CH, Uitdehaag BMJ. Proxy ratings from multiple sources: Disagreement on the impact of multiple sclerosis on daily life. European Journal of Neurology. 2008; 15(9):933-939.
123. Vercellino M, Votta B, Condello C, et al. Involvement of the choroid plexus in multiple sclerosis autoimmune inflammation: A neuropathological study. J Neuroimmunol. 2008; 199(1-2):133-141.
124. Vikman T, Fielding P, Lindmark B, Fredrikson S. Effects of inpatient rehabilitation in multiple sclerosis patients with moderate disability. Adv Physiother. 2008; 10(2):58-65.
125. Vollmer T, Panitch H, Bar-Or A, et al. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Multiple Sclerosis. 2008; 14(5):663-670.
126. von Budingen HC, Harrer MD, Kuenzle S, Meier M, Goebels N. Clonally expanded plasma cells in the cerebrospinal fluid of MS patients produce myelin-specific antibodies. Eur J Immunol. 2008; 38(7):2014-2023.
127. Vyshkina T, Kalman B. Autoantibodies and neurodegeneration in multiple sclerosis. Laboratory Investigation. 2008; 88(8):796-807.
128. Warlop NP, Achten E, Debruyne J, Vingerhoets G. Diffusion weighted callosal integrity reflects interhemispheric communication efficiency in multiple sclerosis. Neuropsychologia. 2008; 46(8):2258-2264.
129. White LJ, Castellano V. Exercise and brain health -- implications for multiple sclerosis: Part II -- immune factors and stress hormones. Sports Med. 2008; 38(3):179-186.
130. White LJ, Castellano V. Exercise and brain health - implications for multiple sclerosis: Part 1 -- neuronal growth factors. Sports Med. 2008; 38(2):91-100.
131. Wiesemann E, Deb M, Hemmer B, Radeke HH, Windhagen A. Early identification of interferon-beta responders by ex vivo testing in patients with multiple sclerosis. Clinical Immunology. 2008; 128(3):306-313.
132. Ytterberg C, Johansson S, Andersson M, Widen Holmqvist L, Von Koch L. Variations in functioning and disability in multiple sclerosis: A two-year prospective study. J Neurol. 2008; 255(7):967-973.
133. Zahariou A, Karamouti M, Karagiannis G, Papaioannou P. Maximal bladder capacity is a positive predictor of response to desmopressin treatment in patients with MS and nocturia. International Urology & Nephrology. 2008; 40(1):65-69.
If you would like to receive additional bulletin, please tick the bulletins you would like to receive, ensure your name and address are on the front cover and return to thelibrary address given overleaf.
| A&E | Healthcare Associated Infection |
| Allied Health Professionals | Healthy Heart |
| Alzheimer’s disease | IT |
| Ambulatory care | Lung Cancer |
| Anaesthesia | Medicine for the Elderly |
| Asthma | Multiple Sclerosis |
| Burns/Dermatology/Plastics | Neonatal Nursing and Midwifery |
| Cancer: Pain | New Books |
| Cancer Supportive Care | New Books (all sites & Nursing) |
| Chaplain | New Nurse |
| Child Protection | Nutrition |
| Clinical Governance | Orthopaedics |
| Community Child Health | Paediatric Anaesthesia & Pain |
| Community Nursing | Paediatric Oncology Nursing |
| Complaints | Paediatric Physiotherapy |
| Coronary Intensive and High Dependency Care | Paediatric Respiratory Medicine |
| Corporate Services | Parkinson’s disease |
| Day surgery | Pharmacy |
| Dental Care Professionals | Prevention & Treatment of Alcohol & Drug Abuse |
| |(Nursing) |
| Dentistry | Primary Care Mental Health |
| Digestive Diseases | Rheumatology |
| Elderly Care Bulletin (Nursing) | Sarcoma |
| Epilepsy | School nurses |
| Guidelines | Speech and Language Therapy |
| Gynaecologic Oncology | Spinal Injuries |
| Head Injury | Stroke (North Glasgow) |
| Health Promotion | Stroke (South Glasgow) |
| | Training, education and Management (Nursing) |
How to Access Electronic Articles
Many of the articles in this bulletin will be available online at the NHS Scotland eLibrary
1. Go to the NHS Scotland eLibrary
2. Click on Journals
3. Type in the journal title and click search.
4. Click on the appropriate title, then select the supplier you wish to use.
5. Put in your Athens password at the “Athens login” link.
6. Select the correct year, volume, issue and page number for the article you want.
Please note, the articles you are accessing may be protected by copyright legislation, please contact your librarian for a copyright declaration form if you are in any doubt. Or, consult the Copyright Licensing Agency at
If you have any questions regarding this or any other library services please contact your librarian.
Compiled by C. Boulnois
Library Services Manager
NHS Greater Glasgow & Clyde Library Network
Central Library
Southern General Hospital
1345 Govan Rd
Glasgow
G51 4TF
0141 201 2163
charlotte.boulnois@sgh.scot.nhs.uk
-----------------------
[pic]
Library Network
Multiple Sclerosis
September 08
Current Awareness Bulletin
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.